Compare POLA & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POLA | OGEN |
|---|---|---|
| Founded | 1979 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 3.6M |
| IPO Year | 2016 | N/A |
| Metric | POLA | OGEN |
|---|---|---|
| Price | $1.98 | $0.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.8K | ★ 93.8K |
| Earning Date | 11-19-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,326,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.53 | $0.82 |
| 52 Week High | $5.75 | $18.90 |
| Indicator | POLA | OGEN |
|---|---|---|
| Relative Strength Index (RSI) | 29.91 | 32.77 |
| Support Level | $2.15 | $0.85 |
| Resistance Level | $2.23 | $0.99 |
| Average True Range (ATR) | 0.13 | 0.06 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 4.00 | 1.90 |
Polar Power Inc is engaged in designing, manufacturing, and selling DC power generators, renewable energy, and cooling systems for applications in the telecommunications market and, to a lesser extent, in other markets, including military, electric vehicle, marine, and industrial. The company's products include DC generators, backup DC generators, hybrid power systems, Li-Ion battery systems, Marine DC generators, and others. The company's geographical presence is in the United States, Canada, Australia and South Pacific Islands, Asia, Europe and Middle East, United Kingdom, Other North America, South Africa, and others.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.